Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 12/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24414772 | 0.94 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRNA7NPC1TP53 | |
| SCHEMBL16098695 | 0.79 | CHRNB4 (0.66) | CHRNB4CHRNA3CHRNA7NPC1RAB9A | |
| SCHEMBL24233984 | 0.79 | CHRNB4 (0.64) | CHRNB4CHRNA3CHRNA7TP53ALDH1A1 | |
| SCHEMBL895500 | 0.78 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7RAB9AALDH1A1 | |
| SCHEMBL19253727 | 0.78 | CHRNB4 (0.63) | CHRNB4CHRNA3CHRNA7NPC1RAB9A | |
| SCHEMBL6797483 | 0.77 | CHRNB4 (0.96) | CHRNB4CHRNA3CHRNA7RAB9AALDH1A1 | |
| SCHEMBL4967805 | 0.74 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL17353143 | 0.73 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNA7NPC1RAB9A | |
| SCHEMBL4693339 | 0.72 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRNA7NPC1TP53 | |
| SCHEMBL15665457 | 0.72 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-117802177-A | Method for synthesizing single chiral 2-aryl substituted nitrogen heterocyclic derivative by imine reductase catalysis and application thereof | 南京药石科技股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| CN-109988091-B | Preparation method of imine compound | 苏州大学 | 2022-03-18 | — | — | CN | disclosed |
| US-8580956-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580956-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20100255005-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-10-07 | — | — | US | disclosed |
| US-20100255005-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-10-07 | — | — | US | disclosed |
| WO-2008153792-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100255005-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CHRNB4 162/4885CHRNA3 114/4885CHRNA7 209/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB4 3299/4885CHRNA3 2163/4885CHRNA7 1575/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | CHRNB4 3299/4885CHRNA3 2163/4885CHRNA7 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.